FDAsafety guidance72% confidence
Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · Pharmacokinetics
- Sub-indication
- General
Related signal: Merck's MK-1403 Trial Targets Type 2 Diabetes and hsCRP Levels